Mutations: APP KM670/671NL (Swedish)
Modification: APP: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: B6.D2-Tg(Thy1-APPSwe)71Blt; B6.D2-Tg(Thy1-APPSwe)72Blt
Genetic Background: C57BL/6, DBA/2, crossed to C57BL/6
Availability: Available through Laurence Ozmen
Amyloid plaques by 17-18 months in the neocortex and hippocampus with detection of five to ten-fold more Aβ40 than Aβ42. Plaque burden significantly lower than in the double transgenic PS2APP. Lower levels of insoluble Aβ40 and Aβ42 than the PS2APP mouse at 16-18 months (Richards et al., 2003).
Transgene with human APP (isoform 751) with the Swedish mutation driven by the Thy1.2 promoter.
This line of mutant APP mice was used to generate a double transgenic animal, PS2APP, by breeding to PS2(N141I) mice (Richards et al., 2003). The construct used to generate these mice was also co-injected with the construct expressing PSEN2(N141I) into C57Bl/6 zygotes to generate another double transgenic line, 152H, which is also known as PS2APP (Ozmen et al., 2009).
Contact Laurence Ozmen.
Research Models Citations
- Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 2003 Oct 1;23(26):8989-9003. PubMed.
- Ozmen L, Albientz A, Czech C, Jacobsen H. Expression of transgenic APP mRNA is the key determinant for beta-amyloid deposition in PS2APP transgenic mice. Neurodegener Dis. 2009;6(1-2):29-36. PubMed.
- Page RM, Baumann K, Tomioka M, Pérez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H, Haass C. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem. 2008 Jan 11;283(2):677-83. PubMed.